Shared decision-making emerged in the 1970s as a response to growing concerns about medical paternalism and the expanding power of medical science to transform lives.The term was formally adopted by the 1982 President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research to underscore the key role of patients in the decision process. The framework reflected a legitimate ethical insight: that patients deserve to participate in decisions about their own care, with full information about risks and benefits, guided by clinicians who respect their values.
What often goes unmentioned in public health debates is how a normative concept in medical ethics can be strategically repurposed.The new U.S. guidelines recommend all children get vaccines for 11 diseases, compared with the 18, including Covid, previously on the schedule.The vaccines that are recommended based on shared clinical decision-making are for rotavirus, the flu, hepatitis A, hepatitis B and bacterial meningitis. On its surface, the language of shared decision-making sounds reasonable. Yet the strategic calculus here involves several competing considerations about what the framing actually signals.
The shifting framework now implies "that the people who provide their health care are not telling them things, not informing them adequately unless there's a shared clinical decision-making recommendation. And that couldn't be further from the truth," said Kelly Moore, MD, MPH, the former director of the Tennessee Immunization Program who is now CEO of Immunize.org. The critical distinction centres on how the category functions:Importantly, SCDM recommendations are not related to any concerns about vaccine safety. In some cases, such as for meningococcal B, data related to vaccine effectiveness may be limited. Due to these data limitations at the time of the recommendation, the relative societal cost per case prevented, and the low number of cases, an SCDM recommendation was implemented.
The distinction matters because observers worry about the messaging effect.Because the term has often been associated with gray areas, in which no one option is most medically advisable, many are concerned that the federal government's usage gives a false impression of balance, suggesting — inaccurately — that the decades of data behind something like the hepatitis B vaccine is equivocal about its benefit.The introduction of shared clinical decision-making presents a false reality that there is no discussion happening between providers and patients. The decision also included a nod to a common trope in the anti-vaccine movement: that vaccines are given without proper informed consent.
A counterargument does exist within the medical community.Vaccination decisions belong to patients and their parents, guided by candid advice from health care professionals, according to some analysts who argue that even strong recommendations should remain subject to informed discussion. Yet even these defenders of shared decision-making distinguish between the concept and its current deployment.Labeling certain vaccines as SCDM risks reinforcing the false signal that evidence is weaker, even when clinical conversations have not meaningfully changed.
The institutional impact reveals the deeper concern.Deleting automatic electronic medical record alerts when shots are due and canceling standing orders for nurses and pharmacists to vaccinate kids without getting a doctor involved shifts the burden from a default presumption toward vaccination to a requirement that every case be negotiated anew.Most patients/parents do not know what shared clinical decision-making really means. Instead of empowering them in their decision-making, it's actually causing more confusion.Federal officials justified the demotion of these six vaccines by looking at peer nations' vaccine schedules and choosing an outlier with the lowest number of vaccines on its schedule, Denmark, to model the U.S. schedule after. It is unclear why Denmark was chosen, considering it is a much smaller country that provides universal free health care, unlike the U.S.
The strategic value of the terminology is apparent to observers on both sides of the vaccine debate.However, the MAHA-aligned Independent Medical Alliance (IMA) praised the recent change of course. "This is a long-overdue recalibration of the number of vaccines administered to newborns and young children at the very outset of life," IMA president Joseph Varone, MD, said in a statement. "HHS took a definitive step toward restoring balance, showing a strong willingness to continue questioning status-quo medical assumptions, and instead place the long-term well-being of children ahead of institutional pressures.
What remains genuinely complex is whether any recalibration of vaccine recommendations was warranted by new evidence.The evidence for rotavirus, influenza, hepatitis B, and meningococcal vaccines has not changed. What has changed is the willingness of federal officials to let that evidence guide policy. The institutional challenge is thatMajor changes to the childhood vaccine schedule, maintained by the CDC, could result in a deeper balkanisation of state public health policies. States often use the CDC list to establish school entry requirements.
The episode illustrates how language developed for one purpose—protecting patients from unquestioned physician authority—can be repurposed to achieve a different outcome: signalling systemic doubt about medical recommendations without formally withdrawing them. Whether one views this as a legitimate reassertion of individual choice or an erosion of public health authority depends substantially on how one weighs competing values: deference to professional expertise versus skepticism of institutional authority, presumptive health protection versus opt-in choice. The analytical difficulty is that both concerns contain legitimate elements. What remains evident is that the vocabulary of shared decision-making now means different things to different stakeholders.